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Muscle-derived cells have been successfully isolated using a variety of different methods and have been shown 
to possess multilineage differentiation capacities, including an ability to differentiate into articular cartilage 
and bone in vivo; however, the characterization of human muscle-derived stem cells (hMDSCs) and their bone 
regenerative capacities have not been fully investigated. Genetic modification of these cells may enhance their 
osteogenic capacity, which could potentially be applied to bone regenerative therapies. We found that hMDSCs, 
isolated by the preplate technique, consistently expressed the myogenic marker CD56, the pericyte/endothelial 
cell marker CD146, and the mesenchymal stem cell markers CD73, CD90, CD105, and CD44 but did not 
express the hematopoietic stem cell marker CD45, and they could undergo osteogenic, chondrogenic, adipo-
genic, and myogenic differentiation in vitro. In order to investigate the osteoinductive potential of hMDSCs, 
we constructed a retroviral vector expressing BMP4 and GFP and a lentiviral vector expressing BMP2. The 
BMP4-expressing hMDSCs were able to undergo osteogenic differentiation in vitro and exhibited enhanced 
mineralization compared to nontransduced cells; however, when transplanted into a calvarial defect, they failed 
to regenerate bone. Local administration of BMP4 protein and cell pretreatment with N-acetylcysteine (NAC), 
which improves cell survival, did not enhance the osteogenic capacity of the retro-BMP4-transduced cells. 
In contrast, lenti-BMP2-transduced hMDSCs not only exhibited enhanced in vitro osteogenic differentiation 
but also induced robust bone formation and nearly completely healed a critical-sized calvarial defect in CD-1 
nude mice 6 weeks following transplantation. Herovici’s staining of the regenerated bone demonstrated that 
the bone matrix contained a large amount of type I collagen. Our findings indicated that the hMDSCs are likely 
mesenchymal stem cells of muscle origin and that BMP2 is more efficient than BMP4 in promoting the bone 
regenerative capacity of the hMDSCs in vivo.
Key words: Human muscle-derived stem cells (hMDSCs); Lentiviral vector; Bone morphogenetic 
 protein 2 (BMP2); Bone morphogenetic protein 4 (BMP4); Retroviral vector; Calvarial defect
INTRODUCTION
Healing of segmental bone defects and fracture non-
unions pose a real challenge for clinical orthopedics; 
however, the development of new biological approaches 
that can address these hurdles is gaining momentum. 
Considerable progress toward repair or replacement of 
diseased or damaged bone tissue, using cell-based tissue 
engineering, has been made over the last decade. Bone 
marrow mesenchymal stromal (stem) cells (BMMSCs) 
have been considered an ideal autologous progenitor cell 
source for enhancing bone repair. It has been reported 
in clinical studies over the past decades that autologous 
human BMMSCs are highly effective, in combination 
with scaffolds, for the treatment of fracture nonunions, 
bone defects, and enhancing the effects of bone length-
ening during distraction osteogenesis (6,16,23,40,42). 
In some situations, however, there are limitations with 
the availability of healthy bone marrow in patients; 
moreover, the harvesting procedure is invasive. The 
use of human adipose-derived stem cells has recently 
gained greater attention and has been shown to promote 
bone formation and bone defect healing in various ani-
mal models (2,8,21,27); however, their bone regenera-
tive capacity is not optimal and has been hindered by 
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several limitations (5,18,28). A recent study by Chou et 
al. demonstrated that human adipose stem cells could 
not improve segmental bone defect repair (4). It has 
also been demonstrated that rat adipose-derived stem 
cells readily form fat tissue compared to bone marrow-
derived stem cells during the bone regeneration pro-
cess (30); therefore, identifying other adult stem cell 
sources will provide additional options for future clini-
cal applications.
Skeletal muscle tissue is easily accessible for orthopedic 
surgeons in the clinic. Human muscle-derived cells have 
been successfully isolated using a variety of  different meth-
ods and have been shown to possess multilineage differen-
tiation capacities. The migratory cells from human cranial 
facial muscles, selected using the surface marker CD56, 
can undergo myogenic, adipogenic, and osteogenic dif-
ferentiation in vitro (41). In another study, Mastrogiacomo 
and colleagues isolated muscle-derived cells by selecting 
cells that adhered to the culture plate after 72 h in culture. 
These muscle-derived cells expressed vimentin, desmin, 
and a-sarcomeric actin and several osteogenic  markers 
including alkaline  phosphatase (AP), type I collagen, 
osteonectin, and osteopontin; moreover, they underwent 
adipogenic, chondrogenic, and osteogenic differentiation 
in vitro, and they could also form ectopic bone in vivo (31). 
More recently, it has been reported that muscle- derived 
cells that adhered to the culture plate after 24 h could be 
separated into two distinct populations, cluster of differ-
entiation 56 positive (CD56+) and CD56−. Both popula-
tions expressed the mesenchymal stem cell markers CD73, 
CD90, CD105, CD44, and CD166 and were negative for 
the hemopoetic stem cell marker CD45. Interestingly, the 
CD56+ cells expressed CD146, while the CD56− cells 
expressed CD15. The CD56+ cells easily underwent myo-
genic differentiation, but their adipogenic differentiation 
capacity was limited. The CD56− cells underwent adipo-
genic differentiation with a limited myogenic differentia-
tion capacity, although both populations could differentiate 
toward an osteogenic lineage (24). Myoendothelial cells 
isolated by flow cytometry based on their expression of 
CD56+CD34+CD144+CD146− from human skeletal  muscle 
have also been shown to be multipotent (47). It has also 
been shown that primary human muscle-derived cells 
transduced with adenoviral bone morphogenetic protein 
2 (adeno-BMP2) or retroviral (retro)-BMP2 could induce 
ectopic bone formation and promote critical-sized calva-
rial defect healing in severe combined immunodeficient 
(SCID) mice (25,33);  however, the osteogenic potential of 
human muscle-derived stem cells (hMDSCs) has not been 
broadly  investigated, and their ability to regenerate bone 
has yet to be determined.
In this study, we isolated hMDSCs, which are likely 
the human counterparts of mouse muscle-derived stem 
cells and were found to highly express mesenchymal 
stem cell markers and undergo multipotent differen-
tiation in vitro. Furthermore, we compared the effect 
that two different bone morphogenetic protein genes 
(BMP2 and 4) genetically constructed into two different 
viral vectors (lenti- and retroviral vectors, respectively) 
for their capacity to promote hMDSC bone regenera-
tion. We constructed a retro-BMP2/4-green fluorescent 
protein (GFP) virus expressing BMP4 and GFP and 
a lenti-BMP2 virus expressing BMP2 in order to test 
their potential for hMDSC-mediated bone regeneration 
in combination with two different scaffolds, including 
fibrin sealant and Gelfoam. The retro-BMP2/4GFP-
transduced hMDSCs did not induce bone formation 
within the critical-sized calvarial defects created in 
the two immunodeficient mouse strains using either of 
the scaffolds. In contrast, the lenti-BMP2-transduced 
 hMDSCs displayed a remarkable bone regeneration capac-
ity in vivo and nearly completely healed the calvarial 
bone defects created in CD-1 nude mice. Our findings 
suggest that BMP2 is more efficient than BMP4 in terms 
of its ability to promote the bone regenerative capacity 
of hMDSCs in vivo.
MATERIALS AND METHODS
Isolation of hMDSCs
Human skeletal muscle tissues obtained from two 
male donors (21 and 23 years old) and two female donors 
(30 and 76 years old) were purchased from the National 
Disease Research Interchange (NDRI, Philadelphia, PA, 
USA). All procedures were approved by the Institutional 
Review Board at the University of Pittsburgh. hMDSCs 
were isolated using a previously described modified pre-
plate technique (14). Briefly, the human muscle tissues 
were cut into small pieces and subjected to collagenase 
type XI (Sigma-Aldrich, St. Louis, MO, USA) and dispase 
(Invitrogen, Darmstadt, Germany) digestion sequentially. 
The single cell suspensions were plated into flasks (BD 
Biosciences, Bedford, MA, USA). After 2 h, the floating 
cells were transferred to another flask (the adhering cells 
called pp1) and cultured for another 24 h. The floating cells 
(adhering cells called pp2) were then replated into another 
flask. The replating process was repeated for another four 
times every 24 h. After six times of replating, the floating 
cells were transferred to a new flask and cultured until all 
the cells eventually adhered to the flask. These cells are 
called preplate 6 cells (hMDSC). The cells were cultured 
in proliferation medium (PM) containing Dulbecco’s 
modified Eagle’s medium (DMEM), 20% fetal bovine 
serum (FBS; both from Gibco/Invitrogen, Carlsbad, CA, 
USA), 1% chicken embryo extract (Accurate Chemical 
and Scientific Corporation, Westbury, NY, USA), and 1% 
penicillin and streptomycin (Gibco). Cells were seeded at 
a density of 1,000 cells/cm2, passaged every 3 days, and 
maintained at less than 50% confluence.
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Surface Marker Expression of the hMDSCs
The marker profile of the cells from each donor was 
analyzed by flow cytometry. Briefly, cells at different 
passages (passages 6–13) were detached using trypsin–
EDTA (Gibco), washed, and incubated with anti-human 
 fluorochrome-conjugated antibodies: CD45-allophycocyanin 
(APC)-cyanine 7 (Cy7), CD56-phycoerythrin (PE)-Cy7, 
CD90-APC (1:100, all from Becton Dickinson, Franklin 
Lakes, NJ, USA), CD146-fluorescein isothiocyanate 
(FITC) (1:50, Serotec, Raleigh, NC, USA), CD44-PE 
(1:50, Becton Dickinson), CD73-PE, CD105-PE (1:50, 
both from Invitrogen, Carlsbad, CA, USA), and ligand 
Ulexeuropaeus agglutinin I (UEA-1-PE; 1:75, Biomeda, 
Foster City, CA, USA), for 20 min at 4°C and subse-
quently analyzed on a FACSAria flow cytometer (Becton 
Dickinson). Negative control samples received equiva-
lent amounts of  isotype-matched  fluorophore-conjugated 
antibodies.
Stem Cell Gene Expression of the hMDSCs
The expression of stem cell genes POU class 5 homeo-
box 1 [POU5F1 or octamer-binding transcription factor 4 
(OCT4)] and the Nanog homeobox (NANOG) and sex-
determining region Y (SRY)-box 2 (SOX2) were tested 
using semiquantitative RT-PCR. RNA was extracted from 
nontransduced cells using Qiagen RNeasy mini kits 
(Qiagen, Dusseldorf, Germany). The cDNA was synthe-
sized with a Superscript III cDNA synthesis kit (Invitrogen, 
Frederick, MD, USA) using 500 ng total RNA. The resul-
tant cDNA was diluted with DNAase- and RNAase-free 
water (Promega Corporation, Madison, WI, USA) and 
kept at −20°C for further semiquantitative polymerase 
chain reaction (PCR) analysis. The PCR amplification of 
OCT4, NANOG, and SOX-2 were performed in a 25-µl 
reaction system using a Gotaq PCR kit (Promega). The 
PCR products were verified on a 1% agarose gel (Fisher 
Scientific, Fair Lawn, NJ, USA). The images were cap-
tured with a Bio-Rad Gel Doc system using QuantOne 
software (Bio-Rad, Hercules, CA, USA). Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was used as a 
loading control. Primer sequences are shown in Table 1.
Multipotent Differentiation Capacities of the hMDSCs
hMDSCs were tested for their myogenic, adipogenic, 
chondrogenic, and osteogenic differentiation capacities 
in vitro.
Myogenic Differentiation. Cells (6 × 104) were seeded in 
collagen-coated 12-well plates (Corning Inc., Corning, NY, 
USA). On the second day when the cells reached 100% con-
fluence, the cells were shifted to myogenic medium, which 
contained high-glucose DMEM supplemented with 2% FBS 
and 1% penicillin/streptomycin. The medium was changed 
three times a week for a total of 2 weeks. Myogenic differen-
tiation was determined via the use of antibodies against fast 
myosin heavy chain (fMHC, Sigma-Aldrich, Milwaukee, 
WI, USA; 1:400) and desmin (Sigma-Aldrich,1:20) using 
triple immunofluorescence staining with 4¢,6-diamidino-
2-phenylindoledihydrochloride (DAPI; Molecular Probes/
Invitrogen, Eugene, OR, USA) as a nuclear stain.
Adipogenic Differentiation. Cells (2 × 105) were seeded 
in collagen-coated six-well plates (Corning). On the 
second day when the cells reached 100% confluence, 
the cells were shifted to adipogenic induction medium 
(Lonza, Walkersville, MD, USA) for 3 days and then 
Table 1. Primer Information
Gene Name Accession Number Primers (5¢–3¢)
Product 
Size (bp)
Annealing 
Temperature (°C)
SOX-9 NM_000346.3 F: GCTCAGCAAGACGCTGGGCA 249 55
R: CCGGAGGAGGAGTGTGGCGA
BMPR1B NM_001203.2 F: AGGCCTCCCTCTGCTGGTCC 108 55
R: TTCGCCACGCCACTTTCCCA
BMPR2 NM_001204.6 F: TCCCATGCTGCCACAACCCA 231 55
R: TGGCCGTTCCCTCCTGTCCA
COX-2 NM_000963.2 F: GCGAGGGCCAGCTTTCACCA 225 55
R: CCTGCCCCACAGCAAACCGT
NANOG NM_024865.2 F: TTCCTTCCTCCATGGATCTG 213 58
R: TCTGCTGGAGGCTGAGGTAT
OCT4 NM_002701.4 F: AGTGAGAGGCAACCTGGAGA 273 58
R: GTGAAGTGAGGGCTCCCATA
SOX-2 NM_003106.3 F: CACAACTCGGAGATCAGCAA 294 58
R: GTTCATGTGCGCGTAACTGT
GAPDH NM_002046.4 F: GCCTTCCGTGTCCCCACTGC 211 58
R: CAATGCCAGCCCCAGCGTCA
F, forward; R, reverse; SOX-9, sex-determining region Y box 9; BMPR1B, bone morphogenetic protein receptor 1B; COX-2, 
cyclooxygenase-2; OCT4, octamer-binding transcription factor 4; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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switched to adipogenic maintenance medium (Lonza) 
for 2 days. The noninduced control was cultured in adi-
pogenic maintenance medium for the entire period of 
culture. After three cycles of induction, the cells were 
cultured in adipogenic maintenance medium for another 
7 days. Adipogenic differentiation was determined by 
oil red O (Sigma-Aldrich) staining.
Chondrogenic Differentiation. Cells (2.5 × 105) were ali-
quoted into 15-ml tubes (BD Biosciences), after centrifu-
gation at 800 × g for 5 min, the cells were resuspended in 
chondrogenic basal medium (Lonza) and centrifuged again. 
The cells were then resuspended in complete chondrogenic 
medium [chondrogenic basal medium supplemented with 
10 ng/ml transforming growth factor b3 (Invitrogen)] and 
centrifuged at 500 × g for 5 min. Cell pellets were main-
tained in chondrogenic medium for 21 days with medium 
change three times a week. Chondrogenic differentiation 
was verified by Alcian blue staining (http://www.ihcworld.
com/_protocols/special_stains/alcian_blue.htm).
Osteogenic Differentiation. We also utilized pellet 
cultures for the osteogenic differentiation assay. Cells 
(2.5 × 105) were aliquoted into each 15-ml tube, centri-
fuged, resuspended in osteogenic medium containing 
high-glucose DMEM supplemented with 10% FBS, 1% 
penicillin/streptomycin, 10−2 M b-glycerol phosphate, 
50 µg/ml l-ascorbic acid-2 phosphate, and 10−7 M dex-
amethasone (all Sigma-Aldrich unless previously speci-
fied), and centrifuged at 500 × g for 5 min. Pellets were 
subjected to medium changes three times a week. The 
pellets were monitored by microcomputed tomography 
(microCT; Viva CT40; Scanco Medical, Scanco USA 
Inc., Wayne, PA, USA) every week for 4 weeks to evalu-
ate mineralized matrix deposition. After 4 weeks, pellets 
were embedded in NEG50 freezing medium (Thermo 
Scientific, Kalamazoo, MI, USA) and snap frozen in liq-
uid nitrogen, and 8-µm sections were cut and fixed for 
10 min in 10% neutral buffered formalin (Sigma-Aldrich). 
Mineralization was detected by von Kossa staining using 
an online protocol (http://www.ihcworld.com/_protocols/
special_stains/von_kossa.htm). Osteocalcin (MAB1219, 
1:100; R&D Systems, Minneapolis, MN, USA) immuno-
histochemistry was performed to validate osteogenic dif-
ferentiation. Diaminobenzidine (DAB) staining kit (Vector 
Laboratories, Burlingame, CA, USA) was used to reveal 
the osteocalcin-positive cells. Hematoxylin QS (Vector 
Laboratories Inc.) was used to counterstain nuclei.
Construction of Retro-BMP2/4GFP, Cell Transduction, 
In Vitro Osteogenic Differentiation, and  
Gene Expression Analysis
Retro-BMP2/4GFP was constructed as previously 
described (37,38). The BMP4 signal peptide sequence in 
this construct was replaced with the BMP2 signal peptide 
to increase the secretion level of the recombinant protein 
(36). The GFP tag was inserted downstream of the BMP4 
gene with an internal ribosome entry site to allow the tar-
get gene BMP4 and the tag gene GFP to be expressed as 
separate proteins. hMDSCs were transduced with retro-
BMP2/4GFP at a multiplicity of infection (MOI) of 5 in 
the presence of 8 µg/ml of polybrene (Sigma-Aldrich). The 
viral transduction was repeated three times at 12-h intervals. 
The transduced cells were expanded, and their transduction 
efficiency was evaluated by GFP expression observed via 
fluorescence microscopy. At passage 4 posttransduction, 
the cells were sorted [fluorescence-activated cell sorting 
(FACS), BD FACSAria IIu, Bedford, MA, USA] to obtain 
cells that were 100% positive for GFP expression in order 
to track the donor cells in vivo. The BMP4 secretion level 
was measured using a Human BMP-4 Quantikine ELISA 
Kit (R&D Systems) and expressed as the mean ± SD ng/
million cells/24 h. A pellet culture assay was used to 
evaluate the osteogenic potential of both transduced and 
nontransduced hMDSCs as described above in vitro. To 
identify the genes that might be associated with the osteo-
genic differentiation potential of the hMDSCs, RT-PCR 
for the Sry box-9 gene (SOX-9), bone morphogenetic pro-
tein receptor 1B (BMPR1B), bone morphogenetic protein 
receptor 2 (BMPR2), and cyclooxygenase 2 (COX-2) were 
performed using the methods described above. The primer 
sequences are shown in Table 1.
Transplantation of Retro-BMP2/4GFP-Transduced 
hMDSCs Into a Calvarial Bone Defect
All animal protocols were approved by the Institutional 
Animal Care and Use Committee of the University of 
Pittsburgh. Three immunocompromised animal mod-
els, B6 SCID, SCID-beige, and CD-1 nude mice, were 
used to evaluate whether the strain of the host animal 
affected the bone regeneration capacity of the hMDSCs. 
Retro-BMP2/4GFP-transduced hMDSCs were trypsinized, 
resuspended in phosphate-buffered saline (PBS) to a final 
concentration of 1.5 × 106/10 µl and seeded on Gelfoam 
(Ethicon, Somerville, NJ, USA) that has been cut into 
6 mm × 6 mm pieces and placed into a 24-well plate. After 
the cell suspension completely soaked into the Gelfoam, 
1 ml of PM was added to each well, and the plate was 
incubated overnight in 5% CO2 at 37°C. Male B6 SCID 
mice (Jackson Laboratory, Bar Harbor, ME, USA) were 
randomly divided into three groups (n = 4). Animals in 
group 1 received 1.5 × 106 retro-BMP2/4GFP-transduced 
hMDSCs using Tisseel fibrin sealant including throm-
bin and fibrinogen (Baxter Healthcare Corporation, 
Westlake Village, CA, USA) scaffold, group 2 received 
1.5 × 106  retro-BMP2/4GFP-transduced hMDSCs seeded in 
Gelfoam, and group 3 received 5 × 105 retro-BMP4GFP-
transduced murine muscle-derived stem cells [mMDSCs; 
obtained from C57BL/10J mice (Jackson Laboratory) 
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using previously described protocol], which served as 
a positive control using Tisseel fibrin sealant scaffold. 
Critical-sized 5-mm-diameter calvarial (skull) defects 
were created in mice under general inhalation anesthe-
sia (3% isoflurane and oxygen) using a trephine (Fine 
Science Tools, Foster City, CA, USA) after removing the 
periosteum. When using Tisseel fibrin sealant, 10 µl of 
the cells combined with 15 µl of thrombin was applied 
to the bone defect first, and then 15 µl of fibrinogen was 
added, allowing 1 min for it to solidify before wound 
closure with sutures (Ethicon LLC, Johnson Johnson, 
San Lorenzo, Puerto Rico). The Gelfoam scaffolds 
seeded with cells were gently rinsed in PBS and applied 
to the defect followed by wound closure with sutures. 
Bone regeneration was monitored by microCT at 2, 4, 
and 6 weeks postimplantation. After 6 weeks, the ani-
mals were sacrificed, and skull tissues were harvested, 
snap frozen in NEG50 medium with liquid nitrogen, and 
stored at −80°C.
In another set of experiments, we either applied 500 ng of 
BMP4 protein (R&D Systems) locally or treated the retro-
BMP2/4GFP-transduced hMDSCs before transplantation 
with N-acetylcysteine (NAC, Sigma-Aldrich) to enhance cell 
survival. In short, retro-BMP2/4GFP-transduced hMDSCs 
were cultured in PM and expanded. NAC was added to the 
flasks at a concentration of 10 mM, and cells were allowed 
to grow for another 24 h. Both treated and untreated cells 
were trypsinized, washed, and resuspended in PBS to a 
final concentration of 1.5 × 106 cells/10 µl. Eight-week-
old male CBGCBS SCID mice (C.B-Igh-1b/GbmsTAC-
PrkdcSCID, aka SCID/Beige, Taconic, Hudson, NY, USA) 
were divided into the following three groups (n = 4): group 
1 received 500 ng BMP4 + Tisseel fibrin sealant; group 2 
received retro-BMP2/4GFP-transduced hMDSC + 500 ng 
BMP4 + Tisseel fibrin sealant; and group 3 received NAC-
treated retro-BMP2/4GFP-transduced hMDSC + 500 ng 
BMP4 + Tisseel fibrin sealant. Animal surgery was per-
formed as previously described, and the healing of the bone 
defect was monitored biweekly by microCT for 8 weeks. 
The mice were then sacrificed, and the skulls were pro-
cessed for histological evaluation. Some animals in group 
2 were sacrificed at day 7 and day 21 posttransplantation to 
investigate cell survival. Dual-color immunofluorescence 
was used to detect the infiltration of neutrophils using rat 
anti-granulocyte receptor-1 (Gr-1) antibody (1:100 dilu-
tion, BD Bioscience, San Jose, CA, USA) and vascular 
endothelial cells using rat anti-CD31 antibody (1:300 
dilution, BD Bioscience) and colocalized with rabbit anti-
GFP antibody (Ab290, Abcam, Cambridge, MA, USA). 
Donkey anti-rat-594 and donkey anti-rabbit-Cy2 second-
ary antibodies (Jackson Immunoresearch Laboratory, West 
Grove, PA, USA) were used to reveal Gr-1 and CD31, and 
GFP, respectively. Nuclear counter staining was performed 
using DAPI.
Evaluation of the Effect of BMP4 Stimulation on 
hMDSC Proliferation
In order to investigate whether BMP4 could affect the 
proliferation of hMDSCs, we performed an in vitro prolif-
eration assay. Two thousand cells were plated in each well 
of a 24-well plate. A recombinant human BMP4 (rhBMP4; 
R&D Systems) stock solution was prepared according to 
the manufacturer’s directions in order to achieve final con-
centrations of 100, 50, 25, and 0 ng/ml. Cells were cultured 
in PM as stated above. For the 3-day stimulation experi-
ment, rhBMP4 was added on day 1. For the 5-day stimula-
tion experiment, the same amount of rhBMP4 was added 
on days 1 and 3. C2C12 murine myoblast cell line (ATCC, 
Manassas, VA, USA) was used as a positive control to test 
the bioactivity of the rhBMP4 protein. After stimulation, 
the cells were washed with PBS, and the DNA content was 
measured using a Quant-iTTM Picogreen double-stranded 
DNA (dsDNA) assay kit (Molecular Probes/Invitrogen). 
Briefly, cells in each well were lysed in 200 µl of 0.1% 
Triton X-100 (Sigma-Aldrich) for 20 min, incubated at 
37°C for 10 min, and then homogenized well by pipetting. 
The cells were kept at −80°C for 2 h, mixed, and incubated 
at 37°C for another 10 min. Fifty microliters of the cell 
lysate was transferred to a nontransparent 96-well plate 
(Becton Dickson & Company, Franklin Lakes, NJ, USA), 
and 50 µl of Tris-EDTA (TE; Sigma-Aldrich) buffer and 
100 µl Picogreen were added following incubation for 
10 min. The fluorescent intensity was measured via a plate 
reader (Tecan Infinite M200, Männedorf, Switzerland). 
Fluorescent intensity represents the amount of double-
stranded DNA that correlates to the cell number. Alkaline 
phosphatase (AP) staining was performed using 86C kit 
(Sigma-Aldrich) to test for osteogenesis.
Construction of the Lenti-BMP2 Vector, Transduction of 
hMDSCs, and In Vitro Osteogenic, Chondrogenic, and 
Myogenic Differentiation After Transduction
The human BMP2 gene in the lentiviral vector was under 
the control of the human cytomegalovirus (CMV) pro-
moter. An SV40 early promoter was inserted downstream 
of the BMP2 expression cassette to drive a higher level 
of constitutive expression of an antibiotic resistance gene, 
which allowed for the use of blasticidin (Gibco/Invitrogen) 
to select the BMP2-transduced positive cells. Lenti-
BMP2 virus was packaged using 293T cells (ATCC). The 
hMDSCs were first expanded in PM until they reached 
30% confluence and then transduced with lenti-BMP2 
virus (diluted 1:1 with PM) for 16 h in the presence of 8 
µg/ml of polybrene. The transduced cells were allowed 
to recover in PM for 24 h. At this time, we collected the 
supernatant to quantify BMP2 secretion levels (Quantikine 
BMP2, R&D Systems). The transduced cells were then 
selected by adding 10 µg/ml of blasticidin (Invitrogen, 
Life Technologies) for a 48-h period. After selection, the 
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cells were cultured in PM, and the supernatant from pas-
sages 1, 3, and 5 after blasticidin selection (BLP1-5) was 
collected to measure BMP2 secretion levels, which were 
normalized to ng/million cells/24 h. In addition, AP stain-
ing was performed as stated above. In vitro osteogenic 
pellet culture, chondrogenic pellet culture, myogenic dif-
ferentiation assays, and RT-PCR were also performed for 
the lenti-BMP2-transduced hMDSCs and compared to the 
nontransduced cells, as described above.
Transplantation of Lenti-BMP2-Transduced hMDSCs 
Into a Calvarial Defect in CD-1 Nude Mice
Male CD-1 nude mice (Charles River Laboratories, 
Wilmington, MA, USA) were divided into three groups 
(n = 4). Animals in group 1 received fibrin sealant + 10 µl of 
PBS; animals in group 2 received fibrin  sealant + 1.5 × 106 
retro-BMP2/4GFP transduced-hMDSCs in PBS; animals 
in group 3 received fibrin sealant + 1.5 × 106 lenti-BMP2-
transduced hMDSCs in PBS. New bone formation in the 
defect area was monitored by microCT biweekly for 6 
weeks. Mice were then sacrificed, and the skulls were har-
vested and fixed in 10% neutral buffered formalin, decalci-
fied with 10% EDTA (Fisher Scientific) plus 1% sodium 
hydroxide (Fisher Scientific) for 2 weeks, and embedded 
in paraffin. Herovici’s polychrome staining using 0.05% 
w/v acid fuchsin in picric acid (Sigma Aldrich) and 0.05% 
w/v methyl blue (Sigma Aldrich) in 1% acetic acid v/v 
(Sigma Aldrich) was performed to identify type I collagen-
positive bone matrix formation as described in the literature 
(26,39,43). Images were captured with a Nikon microscope 
(Nikon, Melville, NY, USA) equipped with a Retiga digital 
camera using Q Capture software (Q Imaging, Inc., Surrey, 
BC, Canada).
Microcomputed Tomography Analysis
Bone regeneration within the calvarial bone defect was 
monitored using microcomputed tomography that was 
performed biweekly after surgery. After obtaining two-
 dimensional image slices of the skulls, the view of inter-
est (VOI) was uniformly delineated. Three-dimensional 
reconstructions were created using an appropriate thresh-
old that was kept constant throughout the analyses. The 
newly regenerated bone volume was measured using eval-
uation software provided by the manufacturer. The bone 
morphometry including volume (mm3) and density [milli-
grams hydroxyapatite per cubic centimeter (mg HA/cm3)] 
measurements regarding the nomenclature, symbols, and 
units followed the guidelines set by the American Society 
of Bone and Mineral Research (3). The bone defect area 
was measured with Image J software (http://rsbweb.nih.
gov/ij/), and the percentage of bone healing was deter-
mined by dividing the area covered by the newly regener-
ated bone after 2, 4, and 6 weeks posttransplantation by the 
original defect area measured on day 1.
Statistical Analysis
All quantitative data are expressed as the mean ± stan-
dard deviation. Student’s t test was used for comparison 
between the two groups. Analysis of variance (ANOVA) 
and Tukey’s HSD post hoc test was used for multigroup 
comparison. A value of p < 0.05 was considered statisti-
cally significant.
RESULTS
Characterization of hMDSCs
hMDSCs isolated by a modified preplate technique 
were characterized by flow cytometry for several cell lin-
eage markers, including CD45 (leukocytes/hematopoietic 
cells), CD56 (myogenic cells), Ulexeuropaeus agglutinin 
I receptor (UEA-1R, endothelial cells), CD146 (peri-
cytes/endothelial cells), as well as classic mesenchymal 
stem/stromal cell (MSC) markers: CD44, CD73, CD90, 
and CD105. We found that hMDSCs robustly expressed 
CD56, CD146, and all four MSC markers (more than 
99% positive) but not CD45 or UEA-1R (Fig. 1A). 
Quantitative analysis revealed a consistent marker expres-
sion profile in all the hMDSC populations examined 
(Fig. 1B). RT-PCR results revealed that cells from all donors 
expressed the stem cell markers OCT4 and NANOG, 
while cells from two of the donors (23-year-old male and 
76-year-old female) slightly expressed SOX-2 (Fig. 1C). 
In vitro differentiation assays indicated that the hMDSCs 
could undergo adipogenic, chondrogenic, osteogenic, and 
myogenic differentiation as shown by oil red O staining, 
Alcian blue staining, von Kossa staining, and fMHC and 
desmin immunofluorescence, respectively (Fig. 1D).
Retro-BMP2/4GFP Transduction Efficiency and  
In Vitro Osteogenesis
The map of the retro-BMP2/4GFP construct is shown 
in Figure 2A. The BMP4 signal peptide sequence was 
replaced with the BMP2 signal peptide to enhance the 
secretion level of BMP4. Detailed information regarding 
the retro-BMP4GFP vector is shown in Table 2. The trans-
duction efficiency of the hMDSCs was approximately 
50%. After FACS, 100% of the cells were GFP positive 
(Fig. 2B). The BMP4 secretion level, measured by ELISA, 
was 6.19 ± 1.4 ng/million cells/24 h. Nontransduced 
hMDSCs had no detectable BMP4 secretion. The mRNA 
expression levels of the SOX-9, BMPR1B, BMPR2, and 
COX-2 genes did not change after transduction with 
retro-BMP2/4GFP (Fig. 2C). We did not observe any 
AP-positive cells before or after transduction (data not 
shown). MicroCT analysis of the cell pellets cultured in 
osteogenic medium revealed that both nontransduced 
and retro-BMP2/4GFP-transduced hMDSCs underwent 
mineralization in vitro. Retro-BMP2/4GFP-transduced 
hMDSCs began to deposit a calcified matrix at 1 week, 
and the mineralized pellet volume in this group was 
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significantly higher compared to the nontransduced cell 
group at each time point (Fig. 2D). The pellet density was 
also significantly higher in the transduced cell group at 
1 and 2 weeks, but there was no difference between the 
two groups after 3 weeks. von Kossa staining and human 
osteocalcin immunohistochemistry revealed bone matrix 
formation in both pellet groups (Fig. 2E). These results 
suggest that the hMDSCs can undergo osteogenic differ-
entiation in vitro and that retro-BMP2/4GFP transduction 
can enhance the osteogenic potential of the hMDSCs.
Retro-BMP2/4GFP-Transduced hMDSCs Failed to 
Regenerate Bone In Vivo
We further investigated whether the retro-BMP2/ 
4GFP-transduced hMDSCs could regenerate bone tissue 
in vivo and heal a critical-sized calvarial defect. Retro-
BMP2/4GFP-transduced hMDSCs delivered with either 
fibrin sealant or Gelfoam scaffold showed only negli-
gible bone regeneration at 6 weeks, as demonstrated by 
microCT. In contrast, mMDSCs transduced with retro-
BMP4GFP (BMP4 secretion level 19.1 ng/million/24 h), 
Figure 1. Characterization of the human muscle-derived stem cells (hMDSCs). (A) Flow cytometry analysis of hMDSC surface 
markers revealed robust expression of cluster of differentiation 56 (CD56), CD146, CD44, CD73, CD90, and CD105 but not CD45 
or Ulexeuropaeus agglutinin I receptor (UEA-1R). (B) Quantification of cell lineage marker expression in hMDSCs from four donors 
demonstrated consistency in their cell marker expression profiles. (C) RT-PCR results of stem cell markers. Cells from each donor 
expressed the stem cell markers octamer-binding transcription factor 4 (OCT4) and NANOG, but only a faint expression of sex-
determining region Y box-2 (SOX-2) was detected in cells from two donors (3 and 4). Glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) was used as a loading control. (D) Multipotent differentiation of hMDSCs. hMDSCs undergo adipogenesis (oil red 
 staining), chondrogenesis (Alcian blue staining), osteogenesis (von Kossa staining), and myogenesis as shown by fast myosin heavy 
chain (fMHC) and desmin immunofluorescence. Scale bars: 200 µm.
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which served as a positive control, were able to com-
pletely heal the defect after 4 weeks (Fig. 3A).
In order to further investigate the inability of the retro-
BMP2/4GFP-transduced hMDSCs to form bone in vivo, 
we performed additional experiments in which we used 
CBSCBG SCID mice that are not only deficient in T-cells 
but also lack macrophages and NK cells (http://www.
taconic.com/wmspage.cfm?parm1=1324), instead of using 
SCID mice. In addition, we attempted to boost the osteo-
genic potential of the transplanted cells and enhance cell 
survival. In one group of animals, 500 ng of rhBMP4 pro-
tein was applied locally to the defect site at the time of 
retro-BMP2/4GFP-transduced hMDSC transplantation. 
A second group of animals received retro-BMP2/4GFP-
transduced hMDSCs that were treated in vitro with NAC 
to enhance cell survival. Surprisingly, we did not observe 
bone formation in any of the treatment groups as well as 
the BMP4-only group even after 8 weeks postimplantation 
(Fig. 3B). Immunofluorescent staining performed on regen-
erated tissue samples obtained from animals sacrificed at 7 
Figure 2. Osteogenic differentiation of hMDSCs and retro-BMP2/4GFP-transduced hMDSCs in vitro. (A) Schematic illustration of the 
retro-bone morphogenetic protein 2/4 green fluorescent protein (BMP2/4GFP) vector. (B) The 100% GFP-positive retro-BMP2/4GFP-
transduced hMDSCs were obtained by fluorescence-activated cell sorting (FACS). Scale bars: 200 µm. (C) RT-PCR results indicated no 
significant gene expression changes before and after retro-BMP2/4GFP transduction of the hMDSCs. (D) Microcomputed tomography 
(microCT) evaluation of matrix mineralization of retro-BMP2/4GFP-transduced and nontransduced hMDSCs in the osteogenic pellet 
culture assay. **p < 0.01 compared to nontransduced hMDSCs (n = 4). (E) von Kossa staining of the pellets at 4 weeks showed that 
both transduced and nontransduced hMDSCs underwent osteogenesis. Osteocalcin staining indicated the differentiation of  hMDSCs 
into osteogenic lineage. Scale bars: 100 µm. LTR, long terminal repeat; CMV, cytomegalovirus; IRES, internal ribosome entry site; 
BMPR1B, bone morphogenetic protein receptor 1B; COX-2, cyclooxygenase-2; mg HA/cm3, mg hydroxyapatite per cubic cm.
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and 21 days after surgery demonstrated that GFP-positive 
donor cells (green) were still present within the defect 
area 7 days after implantation. At the same time, we also 
observed Gr-1-positive neutrophil infiltration and the pres-
ence of CD31 vascular endothelial cells, which were of 
host origin. von Kossa staining of the samples obtained 
at 21 days posttransplantation revealed some scattered 
mineralization in the defect area, but the regenerated tis-
sues were predominantly composed of granulation tissue. 
Immunofluorescent staining revealed very few GFP-
positive donor-derived cells, even though host-derived 
CD31-positive vascular cells were detected in the defect 
area (Fig. 3C). These results indicated that the donor cells 
were unable to survive and induce bone formation.
The Effect of BMP4 Stimulation on Proliferation and 
Differentiation of hMDSCs
In order to test whether BMP4 protein had an adverse 
effect on the hMDSCs, we investigated the proliferation 
and differentiation capacity of the hMDSCs after stimula-
tion with rhBMP4 in vitro. We found an increase in the 
hMDSC proliferation after 3 days when the cells were 
stimulated with 50 or 100 ng/ml of BMP4 protein on day 
1 (Fig. 4A). In contrast, when BMP4 protein was applied 
on days 1 and 3, the hMDSC proliferation rate decreased 
in all groups after 5 days in culture, with the greatest 
reduction in proliferation occurring in the 100-ng/ml 
group (Fig. 4B). In order to evaluate the osteogenic dif-
ferentiation capacity of the hMDSCs after BMP4 stim-
ulation, we performed AP staining at 3 and 5 days and 
found that, regardless of the BMP4 dose, the cells did 
not express AP at any time point (Fig. 4C). C2C12 myo-
blasts were used as a positive control and demonstrated 
AP-positive staining after stimulation with 25 and 50 ng/
ml of BMP4 protein for 3 days (Fig. 4D).
Lenti-BMP2-Transduced hMDSCs Exhibited an 
Enhancement of Osteogenic and Chondrogenic 
Differentiation but Did Not Undergo Myogenic 
Differentiation In Vitro
Lentivirus can infect not only dividing cells but also 
nondividing cells; therefore, we constructed a lentiviral 
vector with a full-length human BMP2 gene under the 
control of a CMV promoter. The map and detailed infor-
mation about the lenti-BMP2 construct are shown in 
Figure 5A and Table 2. ELISA results revealed that the 
BMP2 secretion level was 547 ng/million cells/24 h at 
24 h after hMDSC transduction (data not shown). The 
BMP2 secretion level after blasticidin selection at passage 
1 was 18.06 ng/million cells/24 h and remained relatively 
stable at later passages (3.54 and 2.87 ng/million/24 h, 
respectively, for passages 2 and 5 after blasticidin selec-
tion), which indicated integration of the BMP2 gene 
into the genome (Fig. 5B). The nontransduced hMDSC 
supernatant had no ELISA-detectable BMP2. AP stain-
ing, performed after blasticidin selection, revealed that 
the lenti-BMP2-transduced hMDSCs did not increase AP 
expression (Fig. 5C). In vitro multipotent differentiation 
indicated that the lenti-BMP2-transduced cells exhibited 
enhanced osteogenic and chondrogenic differentiation, as 
detected by microCT, von Kossa, osteocalcin, and Alcian 
blue staining; however, they did not undergo myogenic 
Table 2. Comparison of Retro-BMP2/4GFP, Retro-BMP4GFP, and Lenti-BMP2 Vectors
Retro-BMP2/4GFP Retro-BMP4GFP Lenti-BMP2
Vector Retrovirus Retrovirus Lentivirus
Expression of target gene BMP4 and GFP BMP4 and GFP BMP2 
Promoter CMV CMV CMV
Signal peptide BMP2 BMP4 BMP2
Transduction Infection in the presence of 
polybrene (8 µg/ml)
Infection in the presence of 
 polybrene (8 µg/ml)
Infection in the presence of 
polybrene (8 µg/ml)
Infection time 3 times in 36 h 3 times in 36 h 1 time in 16 h
Selection method GFP-based flow cytometry 
cell sorting
GFP-based flow cytometry cell 
sorting
Blasticidin 10 µg/ml for 24 h
Amount of protein 
expressed (ng/million 
cells/24 h)
6 ng of BMP4 in hMDSC 20 ng of BMP4  in mouse MDSC 2.8 ng of BMP2  in hMDSC
Persistency of expression 
overtime
Stable for about 15 passages 
after cell sorting
Stable for about 15 passages after 
cell sorting
Relatively stable and have a 
trend to decrease overtime
Number of transplanted cells 1.5 × 106 0.5 × 106 1.5 × 106
In vivo efficacy to promote 
bone regeneration 
No healing in defect with 
hMDSC
Completely healed the defect 
with mMDSC
70–80% healed the defect 
area with hMDSC
GFP, green fluorescent protein; CMV, cytomegalovirus; hMDSC, human muscle-derived stem cell.
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differentiation (Fig. 5D, E). The mRNA expression of 
SOX-9, BMPR1b, BMPR2, and COX-2 did not change 
after lenti-BMP2 transduction (Fig. 5F).
Lenti-BMP2-Transduced hMDSCs Induced Calvarial 
Bone Regeneration in CD-1 Nude Mice
We transplanted the retro-BMP2/4GFP-transduced 
hMDSCs and lenti-BMP2-transduced hMDSCs into a 
 critical-sized calvarial bone defect created in CD-1 nude 
mice using fibrin sealant as a scaffold and monitored bone 
formation by microCT biweekly. There was no bone forma-
tion at any time point in the control group that received scaf-
fold alone. The retro-BMP2/4GFP-transduced  hMDSCs 
were also unable to induce bone formation in the calvarial 
defect in these animals. In contrast, bone regeneration was 
detected as early as 2 weeks after surgery in the lenti-
BMP2-transduced hMDSC group (hMDSC-lenti-BMP2) 
(Fig. 6A). Quantification of the newly regenerated bone 
area and volume revealed nearly complete defect cover-
age (approximately 80%) and markedly greater volume of 
new bone in the defect area in the lenti-BMP2-transduced 
hMDSC group compared to the other two groups (Fig. 6B 
and C). Two-dimensional microCT images obtained in the 
coronal plane at 6 weeks postimplantation showed that the 
regenerated bone had native bone-like structural charac-
teristics and was well integrated into the surrounding host 
bone (Fig. 7A). Herovici’s staining demonstrated that the 
newly regenerated bone in the lenti-BMP2-transduced 
hMDSC group contained mainly type I collagen-rich bone 
matrix (red), which was similar to the native bone seen on 
Figure 3. Bone regeneration after transplantation of retro-BMP2/4GFP-transduced hMDSCs. (A) No bone formation was detected 
by microCT within the defect area at 42 days after the transplantation of retro-BMP2/4GFP-transduced hMDSCs using either fibrin 
sealant (FS) or Gelfoam (GF) in B6 severe combined immunodeficient (SCID) mice. Complete defect healing was observed 4 weeks 
after the transplantation of retro-BMP4GFP-transduced mMDSCs (mMDSC + FS). (B) No bone regeneration was observed after trans-
plantation of BMP4 stimulation (+BMP4) or NAC treatment plus BMP4 (+BMP4+NAC) retro-BMP2/4GFP-transduced hMDSCs 
in CBSCBG SCID (SCID beige) mice at any time point. (C) Many GFP-positive donor cells (green), granulocyte receptor-1 (Gr-1)-
positive host neutrophils (red), and vascular endothelial cells (red) were found at the defect site 1 week postimplantation, but only a 
very few GFP-positive cells were detected after 3 weeks. Only isolated spots of mineralization were identified in the defect area as 
shown by von Kossa staining (black) at 21 days. Scale bar: 100 µm. DAPI, 4¢,6-diamidino-2-phenylindole, dihydrochloride.
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the contralateral side of the defect. The defects in the scaf-
fold control and retro-BMP2/4GFP-transduced hMDSC 
(hMDSC-retro-BMP2/4GFP) groups displayed mainly 
granulation tissue composed of type III collagen (blue) 
(Fig. 7B, C). The transplantation of three other hMDSC 
populations transduced with lenti-BMP2 demonstrated 
similar results (data not shown). A significant amount of 
new bone was detected in all the animals that received 
different populations of lenti-BMP2-transduced hMD-
SCs, although the BMP2 secretion levels among the dif-
ferent hMDSC populations varied from 0.303 to 1.219 ng/ 
million cells/24 h.
DISCUSSION
The emerging techniques in regenerative medicine 
using the combination of stem cell transplantation and 
gene therapy are very promising and, in the near future, 
may become suitable for clinical application. Skeletal 
muscle is a readily available source of adult stem 
cells, and several investigators have reported that human 
 muscle-derived cells exhibit mesenchymal stem cell char-
acteristics and are capable of differentiating into multiple 
mesodermal phenotypes (adipogenic, chondrogenic, and 
osteogenic) in vitro (17,24,29,41,45,46). Human muscle-
derived cells have also been shown to form bone and car-
tilage in vivo (31).
Our previous studies demonstrated that cells isolated 
from human skeletal muscle and transduced with adeno-
BMP2 or retro-BMP2 could promote ectopic bone forma-
tion and heal critical-sized calvarial defects created in SCID 
mice (25,33). The cell populations used in the above studies 
were mostly cells that would adhere to the flasks within 5 
days after initial plating. These cells were considered to be a 
mixture of fibroblasts, myoblasts, and other muscle progen-
itor cells. In the current study, we used a modified preplate 
technique to isolate muscle-derived stem cells from human 
skeletal muscle, the same technique that has been success-
fully used to isolate murine muscle-derived stem cells (14). 
The cells we defined as hMDSCs are the floating cells that 
do not adhere after 5 days of culture and eventually adhered 
Figure 4. The effect of BMP4 protein stimulation on hMDSC proliferation in vitro. (A) hMDSC proliferation increased after 3 days 
when 50 or 100 ng/ml of BMP4 was added to the culture medium on day 1. (B) hMDSC proliferation decreased after 5 days when BMP4 
was added on days 1 and 3 using three different dosages (25, 50, or 100 ng/ml). *p < 0.05, **p < 0.01 compared to the untreated controls. 
n = 4 in each treatment group. (C) hMDSCs did not express alkaline phosphatase (AP) after BMP4 stimulation at 3 or 5 days. Scale bars: 
200 µm. (D) C2C12 cells expressed AP after BMP4 stimulation for 3 days. Scale bars: 200 µm. dsDNA, double-stranded DNA.
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to the collagen-coated flask after an extended period of time 
(slow-adhering cells). The morphology of the hMDSCs that 
we isolated using this technique were mesenchymal stem 
(stromal) cell-like (flat and fibroblast-like in appearance), 
which is quite different from the murine MDSCs, which are 
usually small and round. Characterization of the  hMDSCs 
by flow cytometry showed that the cells were nearly homo-
geneous in terms of their expression of the myogenic 
marker CD56, the pericyte/endothelial marker CD146, 
and more than 99% of the hMDSCs expressed the classi-
cal mesenchymal stem cell markers CD73, CD90, CD105, 
and CD44. These cells were negative for the hematopoi-
etic stem cell marker CD45 and the endothelial cell marker 
UEA-1R. The in vitro multipotent differentiation assays we 
performed demonstrated that the hMDSCs could differen-
tiate into adipogenic, chondrogenic, osteogenic, and myo-
genic lineages. These results suggested that the hMDSCs 
we isolated were likely mesenchymal stem cells of muscle 
origin, according to the criteria set out by the International 
Society of Cell Therapy (10). Slowly adhering hMDSCs 
have already been shown to possess a better cardiac repair 
ability in comparison to fast-adhering cells (35). In order 
to promote the application of hMDSCs in clinic for bone 
defect healing, we further investigated the osteogenic dif-
ferentiation capacity of the hMDSCs in combination with 
BMP4 and BMP2 gene therapy.
Retro-BMP2/4-transduced mMDSCs have been shown 
to be capable of inducing bone formation and promot-
ing calvarial defect healing (37,38); therefore, we tested 
whether hMDSCs transduced with retro-BMP2/4GFP 
could also induce bone formation and promote bone heal-
ing. We found that both nontransduced hMDSCs and the 
retro-BMP2/4GFP-transduced hMDSCs were capable of 
undergoing osteogenic differentiation in vitro, although the 
BMP2/4GFP-transduced cells formed larger mineralized 
pellets. Furthermore, we found that the hMDSCs endog-
enously expressed the BMP2/4 receptors BMPR1B and 
BMPR2, as well as SOX-9 and COX-2, which are involved 
in endochondral bone formation (1,19,22,34); how-
ever, when the retro-BMP2/4GFP-transduced  hMDSCs 
were transplanted into a calvarial defect created in SCID 
mice, they did not induce bone formation within the 
defect using either fibrin sealant or Gelfoam scaffolds. 
There could be several explanations for the hMDSCs’ 
failure to form bone in vivo including host immune rejec-
tion, insufficient BMP4 secretion levels by the trans-
duced cells, and/or rapid cell death after transplantation. 
Although B6 SCID mice are deficient in T lymphocytes, 
they still possess macrophages, NK cells, and B lym-
phocytes; therefore, we utilized an alternative recipient 
animal strain, C.B-Igh-1b/GbmsTAC-PrkdcSCID mice 
(SCID beige mice), which are deficient in T lymphocytes, 
Figure 5. BMP2 secretion levels and in vitro multipotent differentiation of hMDSC after lenti-BMP2 transduction. (A) Schematic 
illustration of the lenti-BMP2 vector. Red arrows indicate insertion sites of the target BMP2 gene. (B) BMP2 secretion after hMDSC 
transduction and selection with blasticidin at passages 1, 2, and 5. (C) AP staining showed no increase in AP-positive cell (arrow) 
number after hMDSC transduction with lenti-BMP2. (D) Osteogenic differentiation was enhanced after transduction of hMDSCs 
with lenti-BMP2 as shown by von Kossa staining, osteocalcin immunohistochemistry, and microCT. (E) Lenti-BMP2 transduction 
enhanced chondrogenic differentiation but prevented from myogenic differentiation. (F) RT-PCR indicated no significant change in 
osteogenic-related genes after lenti-BMP2 transduction. Scale bars: 200 µm. BLP, passage after blasticidin selection.
BMP2 VERSUS BMP4 FOR hMDSC-MEDIATED BONE HEALING 2405
NK cells, and macrophages in order to examine the role 
of host immune rejection in our future experiments. The 
inability of the retro-BMP2/4GFP-transduced hMDSCs 
to induce bone could also be due to the lower amount of 
BMP4 secreted by the hMDSCs compared to the BMP4 
secreted by the retro-BMP2/4-transduced mMDSCs 
previously reported (37); however, local application of 
BMP4 protein into the defect area during surgery did not 
enhance bone formation. Lastly, the lack of in vivo bone 
formation could be related to rapid death of the hMDSCs 
after transplantation; therefore, we attempted to improve 
the survival of the hMDSCs by treating them with NAC 
before transplantation. It has been reported that mMDSCs 
treated with NAC were capable of improving heart func-
tion after cardiac infarction in comparison to untreated cells 
(11); once again, no improvement in bone formation was 
observed when the NAC-treated cells were transplanted 
into the same calvarial defect model. Unfortunately, all 
these latter attempts to enhance bone formation using the 
retro-BMP2/4GFP-transduced  hMDSCs failed, even in 
SCID beige mice after 8 weeks.
There are very few reports indicating that BMP4 can 
promote human adult stem cell-mediated bone regenera-
tion. BMP4 has been shown to be incapable of promoting 
endosteal bone formation mediated by stem cell antigen-1 
positive (SCA-1+) cells transduced with lenti-BMP2/4 and 
administered via retro-orbital injection in C57BL/6J mice 
that underwent sublethal irradiation (15) and could only 
induce mesenchymal stem cells to undergo osteogenic dif-
ferentiation under low-serum conditions (7). It has also been 
demonstrated that low doses of BMP4 (0.01–0.1 ng/ml) 
could increase human adipose stem cell proliferation and 
maintain their “stemness,” while high doses of BMP4 
(10–100 ng) had adverse effects (44). The fact that the 
proliferation of bone marrow-derived mesenchymal stem 
cells was also inhibited in the presence of higher concen-
trations of BMP4 (100 ng/ml) (12) raised our suspicion 
that BMP4 may also have adverse effects on hMDSCs. 
Figure 6. Bone regeneration after transplantation of lenti-BMP2-transduced hMDSCs. (A) MicroCT images of the different treatment 
groups showed negligible bone formation in the retro-BMP2/4GFP-transduced hMDSCs (hMDSC-retro-BMP2/4GFP) and scaffold 
control groups. In contrast, robust bone formation was observed in the lenti-BMP2-transduced hMDSC (hMDSC-lenti-BMP2) group 
at 2 weeks, and nearly complete defect healing was detected by 6 weeks. (B) Quantification of the calvarial defect area covered by the 
regenerated bone after 6 weeks showed 80%, 10%, and 14% healing in the hMDSC-lenti-BMP2 group, hMDSC-retro-BMP2/4GFP, 
and scaffold control groups, respectively. (C) Quantification of the regenerated bone volume after 6 weeks showed significantly more 
bone in the hMDSC-lenti-BMP2 group compared to the other groups, **p < 0.01, compared to scaffold control, ##p < 0.01, compared 
to the hMDSC-retro-BMP2/4GFP group.
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Indeed, our in vitro results demonstrated that prolonged 
BMP4 stimulation inhibited hMDSC proliferation. On 
the other hand, it is also possible that the transplanted 
 hMDSCs may be subjected to competing environmental 
signals from the host, such as BMP2 signaling. It has 
been reported that BMP2, secreted from the host dura 
mater, can accelerate human adipose-derived stromal cell-
mediated bone regeneration (28). In our case, the retro-
BMP2/4-transduced cells secreted BMP4, while the host 
dura mater secreted BMP2; hence, these two proteins 
may compete for the BMP-binding sites of the receptors 
(BMPR1b and BMPR2) responsible for osteogenic differ-
entiation of the hMDSCs. Therefore, we concluded that the 
proper selection of growth factors plays an important role 
in human stem cell-mediated bone formation.
Lentiviral vectors are human cell specific and randomly 
integrate into the cells’ genome, which is similar to the ret-
roviral vector, and therefore, this virus can promote long-
term exogenous gene expression by the transduced cells. 
Lentiviral vectors are also superior to retroviral vectors 
because they infect both dividing and nondividing cells and 
usually do not require multiple rounds of infection. It has 
been shown in a rat posterolateral spine fusion model that 
lenti-BMP2-transduced rat bone marrow cells resulted in 
spinal fusion, but no fusion was observed using nontrans-
duced and lenti-GFP-transduced cells (32). Lentiviral vec-
tors have been used to transduce human bone marrow stem 
cells to express several different growth factors (13). We 
constructed a lentiviral vector, carrying the human BMP2 
gene and efficiently transduced the hMDSCs, which had 
no effect on their proliferation capacity after cell transduc-
tion. Although BMP2 secretion decreased after selection 
with blasticidin, it continued to be secreted at relatively 
stable levels (2.87 ng/million cells/24 h) during several 
consecutive passages. In addition, the hMDSCs did not 
express AP after lenti-BMP2 transduction indicating that 
the cells remained undifferentiated; however, when they 
were transplanted into a calvarial defect in CD-1 mice, 
they formed new bone as early as 2 weeks and almost com-
pletely healed the defect by 6 weeks. We also have evi-
dence that other hMDSC populations, which secrete even 
less BMP2, can form similar amounts of new bone in vivo 
(unpublished data). These results indicated that appropriate 
levels of BMP2 secretion are required and that induction 
of bone formation can occur even at BMP2 concentrations 
as low as 0.303 ng/million cells/24 h. Moreover, the newly 
formed bone was found well integrated into the surround-
ing native bone as shown by microCT and histology.
Figure 7. Morphometric and histological characteristics of the newly regenerated calvarial bone. (A) MicroCT demonstrated that 
the regenerated bone in the hMDSC-lenti-BMP2 group was similar to the native bone and was well integrated into the surrounding 
host bone. (B) Herovici’s staining of cross sections of skull tissues (20×) showing that the regenerated bone (the area between arrows 
indicate calvarial defect region) in the hMDSC-lenti-BMP2 group was similar to the native bone in the contralateral side (area between 
stars). (C) Higher magnification (200×) of the regenerated bone area (box area in B) showing that hMDSC-lenti-BMP2 group con-
tained mainly type I collagen (red) and was well integrated with the host bone (arrow). The tissue within the defect in scaffold control 
and hMDSC-retro-BMP2/4GFP groups mainly consisted of type III collagen (blue). Scale bars: 100 µm. COL1, type I collagen; COL3, 
type III collagen; Br, brain; BM, bone marrow.
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In conclusion, our study indicates that hMDSCs iso-
lated by the preplate technique are most likely mesen-
chymal stem cells of muscle origin. BMP2 was found to 
be far superior to BMP4 in terms of promoting the bone 
regenerative capacity of hMDSCs in vivo. Moreover, the 
strain of the host mice did not significantly influence the 
bone regenerative capacity of the hMDSCs, provided they 
were immunodeficient. Finally, we demonstrate that the 
bone formation capacity of the hMDSCs is not affected 
by the cell scaffolds used in this study (Gelfoam and 
fibrin sealant), although other scaffolds may. We believe 
these findings provide valuable insights for future inves-
tigations of human muscle-derived stem cell-mediated 
bone regeneration in clinical applications.
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